Oncotelic Therapeutics Analysis

Oncotelic OTC Stock Analysis Notes

About 56.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncotelic Therapeutics had not issued any dividends in recent years. The entity had 1:12 split on the 28th of December 2012. Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.The quote for Oncotelic Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Oncotelic Therapeutics contact Vuong Trieu at 650 635 7000 or learn more at https://www.oncotelic.com.

Oncotelic Therapeutics Investment Alerts

Oncotelic Therapeutics Upcoming and Recent Events

Oncotelic Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncotelic Therapeutics's market, we take the total number of its shares issued and multiply it by Oncotelic Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Oncotelic Therapeutics Outstanding Bonds

Oncotelic Therapeutics Predictive Daily Indicators

OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncotelic Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncotelic shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Oncotelic Therapeutics. By using and applying Oncotelic OTC Stock analysis, traders can create a robust methodology for identifying Oncotelic entry and exit points for their positions.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.